Wanajo Isao, Tomiyama Yoshitaka, Yamazaki Yoshinobu, Kojima Masami, Shibata Nobuo
Central Research Laboratory, Kissei Pharmaceutical Co. Ltd., Nagano, Japan.
J Urol. 2004 Sep;172(3):1155-9. doi: 10.1097/01.ju.0000133557.39515.b6.
We pharmacologically characterized the functional beta-adrenoceptor subtypes mediating porcine ureteral smooth muscle relaxation.
The effects of various beta-adrenoceptor agonists and antagonists on KCl induced tonic contractions in isolated porcine ureteral preparations were evaluated using a functional experimental technique.
The rank order of potency for the catecholamines tested was isoprenaline > adrenaline > noradrenaline. All beta2-adrenoceptor agonists tested (salbutamol, procaterol and terbutaline) attenuated the KCl induced contraction. The 2 beta3-adrenoceptor agonists CL-316243 ((R, R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethylamino]propyl]-1,3-benzodioxole-2,2-dicarboxylate], Kissei, Nagano, Japan) and CGP-12177A ((+/-)[4-[3[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2 H-benzimidazol-2-one hydrochloride], Funakoshi, Tokyo, Japan) also relaxed the ureter. The beta1-adrenoceptor agonist dobutamine had a relaxing effect on the ureter only at high concentrations (over 1 x 10 M). Isoprenaline induced relaxation was antagonized by the beta2-adrenoceptor antagonist ICI-118,551 ((+/-)-1-[(2,3-dihydro-7-methyl-1 H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol hydrochloride, Sigma, St. Louis, Missouri) but not by the beta1-adrenoceptor antagonist CGP 20712A ((+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1 H-imidazol-2-yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulphonate, Funakoshi). In the presence of 1x 10 M CGP 20712A plus 1 x 10 M ICI-118,551 the beta3-adrenoceptor antagonist SR 58894A (3-(2-allylphenoxy)-1-[(1 S)-1,2,3,4-tetrahydronaphth-1-ylamino]-(2 S)-2-propanol hydrochloride, Kissei) antagonized isoprenaline induced relaxation.
Our results suggest that porcine ureteral smooth muscle is relaxed by beta2 and beta3-adrenergic stimulation, as in humans.
我们对介导猪输尿管平滑肌舒张的功能性β-肾上腺素能受体亚型进行了药理学特征分析。
采用功能性实验技术评估了各种β-肾上腺素能激动剂和拮抗剂对氯化钾诱导的离体猪输尿管标本强直性收缩的影响。
所测试的儿茶酚胺的效价顺序为异丙肾上腺素>肾上腺素>去甲肾上腺素。所有测试的β2-肾上腺素能激动剂(沙丁胺醇、丙卡特罗和特布他林)均减弱了氯化钾诱导的收缩。两种β3-肾上腺素能激动剂CL-316243((R, R)-5-[2-[[2-(3-氯苯基)-2-羟乙基氨基]丙基]-1,3-苯并二恶唑-2,2-二羧酸酯],日本长野的Kissei公司)和CGP-12177A((+/-)[4-[3[(1,1-二甲基乙基)氨基]-2-羟基丙氧基]-1,3-二氢-2H-苯并咪唑-2-酮盐酸盐],日本东京的船桥公司)也使输尿管舒张。β1-肾上腺素能激动剂多巴酚丁胺仅在高浓度(超过1×10⁻⁵M)时对输尿管有舒张作用。异丙肾上腺素诱导的舒张被β2-肾上腺素能拮抗剂ICI-118,551((+/-)-1-[(2,3-二氢-7-甲基-1H-茚-4-基)氧基]-3-[(1-甲基乙基)氨基]-2-丁醇盐酸盐,美国密苏里州圣路易斯的Sigma公司)拮抗,但不被β1-肾上腺素能拮抗剂CGP 20712A((+/-)-2-羟基-5-[2-[[2-羟基-3-[4-[1-甲基-4-(三氟甲基)-1H-咪唑-2-基]苯氧基]丙基]氨基]乙氧基]-苯甲酰胺甲磺酸盐,日本东京的船桥公司)拮抗。在存在1×10⁻⁵M CGP 20712A加1×10⁻⁵M ICI-118,551的情况下,β3-肾上腺素能拮抗剂SR 58894A(3-(2-烯丙基苯氧基)-1-[(1S)-1,2,3,4-四氢萘-1-基氨基]-(2S)-2-丙醇盐酸盐,日本长野的Kissei公司)拮抗异丙肾上腺素诱导的舒张。
我们的结果表明,与人类一样,猪输尿管平滑肌通过β2和β3肾上腺素能刺激而舒张。